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Patients entered the model according to three different adhesion states related 
to each treatment drug - fully compliant, partially compliant and non-compliant 
– and could subsequently transition between different health states during each 
monthly cycle. Probability of relapse, level of adherence, treatment discontinuation 
and adverse events associated with each intervention were sourced from literature 
and while resource use was obtained from specialist’s opinion. Costs and outcomes 
were evaluated over a 5-year horizon, and discounted at 5.0%. Exchange rate (1 
USD = 2.30 BRL) Results were presented as incremental costs/relapses avoided. 
Deterministic and probabilistic sensitivity analyses were performed Results: Total 
costs (USD): PP (15,917), OP (13,670), QP (16,845) and ZP (13,273). Hospitalization 
relapses costs (USD): PP (3,114), OP (4,504), QP (6,305) and ZP (6,459). Relapses rate: PP 
(1.15), OP (1.67), QP (2.37) and ZP (2.41). Incremental cost per relapses avoided (USD/
relapses avoided): PP vs. OP (2,247), PP vs. QP (-927), PP vs. ZP (2,644). ConClusions: 
Compared with the drugs under analysis, PP demonstrates savings in terms of 
hospitalization costs. Additionally, PP is a cost-saving strategy compared to QP and 
when compared to OP and ZP, is a cost-effective therapy for the treatment of schizo-
phrenia in adults patients in Brazil.
PMH51
Cost-effeCtiveness of PHarMaCotHeraPy for CHildren and 
adolesCents witH attention difiCit HyPeraCtivity disorder
Chou Y.T.1, Biddle A.K.2
1University of North Carolina at Chapel Hill, Eshelman School of Pharmacy, Chapel Hill, NC, USA, 
2University of North Carolina at Chapel Hill, Gillings School of Global Public Health, Chapel Hill, 
NC, USA
objeCtives: Effective therapy with different drug formulations exists for Attention 
Deficit Hyperactivity Disorder (ADHD), yet poor adherence leads to suboptimal 
long-term effects for children and adolescents with ADHD. This study analyzes 
the cost-effectiveness of medication formulation (long-acting [LA] versus short-
acting [SA]) for ADHD treatments in children and adolescents taking into account 
medication adherence. Methods: We constructed a hybrid decision tree-Markov 
model employing a third-party payer’s perspective. Evaluation included methyl-
phenidate (MPH) and atomoxetine (ATX) with long- and short-acting formulations, 
which resulted in three medication groups for comparison: LA-ATX, LA-MPH, and 
SA-MPH. Only medication costs for ADHD treatments are considered, which were 
retrieved from Consumer Reports Best Buy DrugsTM report. Quality-adjusted life expec-
tancy (QALE) was measured in quality-adjusted life-years (QALYs) considering side 
effects among medication groups. The 5-year discounted incremental costs (in 
2013 US dollars) per QALY (ICER) were reported comparing the three medication 
groups. Sensitivity analyses were performed to test the impact of uncertain model 
parameters on results. Results: Considering medication adherence, the ICERs are 
$18,926/QALY for LA-ATX ($3,417, 4.33 QALYs), $11,335/QALY for LA-MPH ($1,288, 4.26 
QALYs), and $7,816/QALY for SA-MPH ($591, 4.23 QALYs), respectively, compared 
to no treatment. LA medications are consistently cost-effectiveness compared to 
SA medications. In general, the ICERs were insensitive to variation in key param-
eters. ConClusions: LA-ATX, LA-MPH, and SA-MPH are cost-effective alternatives 
for children and adolescents with ADHD when considering medication adherence. 
Treatment with long-acting medications, especially ATX, is associated with better 
health outcomes and higher medication adherence. Given there is little difference 
in health outcomes among the therapies; however, additional research on optimal 
ADHD treatments (pharmacological, behavioral, or combined therapies) is needed.
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bACkgRound/objeCtives: Risperidone is a commonly used antipsychotic for 
the treatment of schizophrenia. Its major metabolic pathway is through the liver 
enzyme CYP2D6. Variants of CYP2D6 confer differing activity levels. Poor metabo-
lizer phenotype is suspected to increase the risk of adverse drug reactions that 
could lead to risperidone discontinuation and poor patient outcomes. The objective 
of this study was to assess the potential costs and outcomes of a pharmacogenetic-
guided risperidone treatment strategy for use in schizophrenics. Methods: A 
decision analytic model was developed to estimate the incremental cost per QALY 
gained (ICER) and cost per relapse and hospitalization avoided, associated with 
a pharmacogenetic-guided strategy compared to a standard treatment approach 
for a hypothetical schizophrenic patient initiated on risperidone. We used a one-
year time horizon and a payer perspective. Model probabilities, costs, and utilities 
were obtained from the literature. One-way sensitivity analyses were performed 
to explore the possible range of results. Results: For one patient entering the 
model, pharmacogenetic-guided treatment increased QALYs (0.00047), and pre-
vented relapses (0.00782) as well as relapse-associated hospitalizations (0.00235) 
at an increased total cost ($167). This resulted in an ICER of $356,356, and costs 
of $21,468 per relapse avoided and $71,561 per hospitalization avoided relative to 
standard treatment. Findings were robust to one-way sensitivity analyses and did 
not change the base case Conclusions. ConClusions: Our results suggest a phar-
macogenetic-guided treatment approach for risperidone may confer a small reduc-
tion in relapses and consequent hospitalizations, and a very minimal increase in 
QALYs for relatively low additional cost compared to standard treatment. However, 
the large ICER suggests this approach is not cost effective.
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than the other two strategies. Compared to clonidine/guanfacine, AAPs provided a 
lower QALY (0.11 QALY lost) at an additional cost of $2,186 on average. Compared to 
atomoxetine, AAPs resulted in 0.10 QALY lost at an additional cost of $2,186. These 
results were robust in sensitivity analyses. ConClusions: In this decision analysis 
model, AAPs provide lower expected health outcomes than other ADHD medications 
(atomoxetine, clonidine, or guanfacine) in children and adolescents who failed prior 
stimulant therapy. Furthermore, AAPs were not a cost-effective option.
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objeCtives: Staying in structured drug treatment for more than 12 weeks is 
a strong predictor of positive outcomes. Higher doses of buprenorphine and 
buprenorphine-naloxone appear to be more effective for retaining clients in treat-
ment, though the incremental cost per retained client associated with each dose is 
unknown. This study estimated cost-effectiveness thresholds for prescribing higher 
doses of buprenorphine/buprenorphine-naloxone to retain individuals in treatment 
for at least 12 weeks. Methods: Dose, treatment duration, and retention data 
were extracted or computed from 14 randomised, controlled, double-blind clinical, 
12-26 week trials of buprenorphine/buprenorphine-naloxone maintenance treat-
ment of opioid-dependent individuals (N = 1,897). Treatment costs included drug 
preparations and supervised consumption of doses. Retention in treatment was 
used as the primary measure of clinical effectiveness. Results: Weighted mean 
treatment retention rates were 49% (2 to 7.9-mg/day), 53% (8 to 15.9-mg/day), 60% 
(16 to 23.9-mg/day) and 58% (24 to 32-mg/day). Controlling for differences in treat-
ment duration, patients dosed with 16 to 23.9-mg/day, 24 to 32-mg/day, and 8 to 
15.9-mg/day were 47% (p = 0.001), 37% (p = 0.275), and 8% (p = 0.498) more likely to 
stay in treatment for 12-26 weeks compared to patients dosed with 2 to 7.9-mg/day. 
Compared to 8 to 15.9-mg/day, a 16 to 23.9-mg/day dose was estimated to yield an 
additional 65 retentions per 1000 patients treated at an additional cost of £74,968 
(incremental cost per retention = £1,158). ConClusions: If UK decision makers’ 
willingness-to-pay to retain one patient in treatment for at least 12 weeks is greater 
than £1,158, then buprenorphine/buprenorphine-naloxone prescribed at a dose of 
16 to 23.9-mg/day may cost-effectively increase the treatment retention rate.
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objeCtives: The risks of smoking during pregnancy are numerous to both mother 
and fetus. While the negative effects of smoking during pregnancy can be long-
term, medical costs that are most easily linked to smoking during pregnancy occur 
shortly following birth. For example, smoking during pregnancy often results in 
prolonged hospitalization and admission of the infant to a neonatal intensive care 
unit (NICU), at a cost of thousands of dollars daily. We set out to perform the first 
health economic analysis of incentive-based treatments in a smoking, pregnant 
population. Methods: The design of the present study was based on analysis of 
recent prospective studies examining the use of contingency management (CM) for 
the treatment of smoking during pregnancy. The resultant pooled analysis totaled 
166 women (82 contingent, 78 non-contingent) for whom clinical outcomes and 
direct hospital costs were reported. Pregnant women who reported smoking upon 
entering prenatal care were recruited from Fletcher Allen Health Care obstetric 
practices and Women, Infants, and Children (WIC) offices in and around Burlington, 
Vermont. Women were randomized between two conditions: contingent or noncon-
tingent vouchers. Those in the contingent condition received vouchers exchange-
able for retail goods contingent upon cotinine-negative urine analysis. Women in the 
non-contingent condition received vouchers independent of their smoking status. 
Vouchers were provided throughout pregnancy and for the first 3 months postpar-
tum. Results: As compared with non-contingent care, CM led to a nearly 3-fold 
reduction in admissions to the neonatal intensive care unit (NICU). Only 7.0% of 
CM women delivered infants admitted to the NICU (median charge = $9,210) versus 
19.2% among non-contingent women (median charge = $11,363). The findings from 
this study suggest that these cash-like incentives targeting at-risk patients are 
not only cost-effective but also cost-saving in pregnant smokers. ConClusions: 
Incentive-based treatment towards smoking abstinence dominated usual care with 
both better outcomes and lower economic costs.
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objeCtives: Schizophrenia is a chronic disorder that requires long-term treatment 
with antipsychotic medication to minimize relapse and provide benefit to patients. 
Due to the long duration of treatment, adherence is an important factor in order to 
avoid relapses and re-hospitalization. Long-acting Injectable (LAI) formulations of 
atypical antipsychotics provide constant medication delivery and thus a potential 
improve in adherence. The aim of this analysis is to assess the cost-effectiveness of 
paliperidone palmitate (PP) relative to olanzapine (OP), quetiapine (QP) and ziprazi-
done (ZP) under the Brazilian Private Healthcare System perspective. Methods: A 
decision-analytic Markov model was developed adopting a monthly cycle length. 
